Invention and characterization of a systemically administered, attenuated and killed bacteria-based multiple immune receptor agonist for anti-tumor immunotherapy
Activation of immune receptors, such as Toll-like (TLR), NOD-like (NLR) and Stimulator of Interferon Genes (STING) is critical for efficient innate and adaptive immunity. Gram-negative bacteria (G-NB) contain multiple TLR, NOD and STING agonists. Potential utility of G-NB for cancer immunotherapy is...
Saved in:
| Main Author: | Michael J. Newman |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2024-11-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2024.1462221/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Pilot clinical trial of neoadjuvant toll-like receptor 7 agonist (Imiquimod) immunotherapy in early-stage oral squamous cell carcinoma
by: Angela J. Yoon, et al.
Published: (2025-01-01) -
Local therapy with combination TLR agonists stimulates systemic anti-tumor immunity and sensitizes tumors to immune checkpoint blockade
by: Francois Xavier Rwandamuriye, et al.
Published: (2024-12-01) -
Eradication of proliferative verrucous leukoplakia with toll-like receptor 7 agonist (topical imiquimod): a case report
by: Melanie Townsend, et al.
Published: (2024-11-01) -
Toll-like receptors in atopic dermatitis: pathogenesis and therapeutic implications
by: Ahmad Vafaeian, et al.
Published: (2025-02-01) -
The role of Toll-like receptor 4 Asp299Gly genetic polymorphism in rehabilitation of patients with post-COVID syndrome
by: Leуla Sh. Dudchenko, et al.
Published: (2024-11-01)